Apollo 24/7 forays into insurance, credit card biz
Simultaneously, Apollo will also launch India's first health-focused credit card in collaboration with a leading issuer. The card will offer exclusive benefits across medicines, diagnostics, doctor consultations, and wellness services, targeting Apollo's 150 million users.
'Apollo 24|7 is on a mission to make healthcare more affordable, integrated, and preventive. With Telangana as a strategic pillar, we're driving the next chapter of digital healthcare in India,' Madhivanan Balakrishnan, CEO, Apollo HealthCo, told the media here on Wednesday. In a bid to promote preventive healthcare, Apollo has launched the 'Ultimate Health Challenge'—a pioneering initiative that refunds the full cost of health check packages to users who receive 100% positive reports. This effort is designed to encourage early detection and proactive health management.
Since launching in 2020, Apollo 24|7 has rapidly evolved into a comprehensive digital healthcare ecosystem. Telangana, especially Hyderabad, has emerged as a key growth region, accounting for 17 per cent of Apollo's nationwide pharmacy sales. With over 900 Apollo Pharmacy stores across the state—500 of them in Hyderabad—the platform fulfills 4.5 million monthly pharmacy orders, making quality medicines available within 1–2 km of most residents.
One of the standout achievements in the region has been the successful pilot of Apollo's 19-minute medicine delivery service, a first-of-its-kind healthcare quick commerce initiative. Over 80,000 orders have been delivered within this record time, and the company plans to expand this service across Hyderabad and eventually throughout Telangana.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
7 hours ago
- Business Standard
Apollo eyes 20-23% growth in new co; says restructuring to unlock value
Apollo Hospitals Enterprise Ltd (AHEL) on Tuesday said its ongoing restructuring aims to unlock the value of its omni-channel pharmacy and digital businesses, while enhancing shareholder returns. The newly formed entity is expected to achieve a year-on-year growth rate of 22–23 per cent, driven by the e-pharmacy segment and other business verticals, with a revenue target of Rs 25,000 crore by FY27. The digital health platform is also expected to break even within the next financial year. On Monday, the Chennai-based AHEL announced plans to spin off its digital health and pharmacy distribution businesses into a separate entity, with plans to list the new entity within 18 to 21 months. As part of the restructuring, the company's omni-channel pharma and digital health business, Apollo HealthCo, will first be demerged from AHEL into a new entity, following which its pharma distribution arm, Keimed, will be merged into the new company. Its current revenue stands at around Rs 16,300 crore. The company has stated plans to achieve a revenue run rate of Rs 25,000 crore by FY27 with 7 per cent EBITDA margins, said Suneeta Reddy, Managing Director, Apollo Hospitals Enterprise. After the entire restructuring process—expected to be completed by the listing of the new company by February 2027—the new entity will include the digital health platform Apollo 24/7, the offline pharmacy business of Apollo HealthCo, Keimed, and the telehealth services business. 'We are looking at a growth of around 22 per cent to 23 per cent on a year-on-year basis. In the first two quarters—Q4 and Q1 of this year—we have been able to beat that number reasonably well, and I believe that traction is on. It will primarily come from the e-pharmacy business, wherein we have started touching around Rs 165 crore to Rs 170 crore on a month-on-month basis between the platform and some of the other supporting engines,' said Madhivanan Balakrishnan, Chief Executive Officer of Apollo HealthCo. 'Both the consult business and the diagnostic business, which we work very closely with Apollo Hospitals, are also showing an uptick. There are two more lines of business which we are adding—one is insurance, which is in the early stages; that will also contribute to growth, not just as a standalone line of business but also as a feeder into our primary pharmacy and healthcare lines of business. 'And third, this year we see a reasonable amount of GMV—also more than GMV—revenue coming from our monetisation initiatives. We are reasonably confident of 20 to 25 per cent growth between both AHEL as well as Keimed once it comes through,' Balakrishnan added.
&w=3840&q=100)
Business Standard
16 hours ago
- Business Standard
Apollo Hospitals shares hit record on plan to list pharmacy, digital biz
Shares of Apollo Hospitals Enterprise Ltd. surged over 4 per cent to hit a record high on Tuesday, after the company said it will spin off and separately list its digital health and pharmacy unit within 18 to 21 months. The hospital firm's stock rose as much as 4.42 per cent during the day to a life high of ₹7,569.5 per share. The stock pared gains to trade 3.5 per cent higher at ₹7,500 apiece, compared to a 0.22 per cent advance in Nifty 50 as of 9:46 AM. Shares of the company saw their steepest intraday gain since November 7 last year. The counter has fallen 2.8 per cent this year, compared to an 8.2 per cent advance in the benchmark Nifty 50. Apollo Hospitals Enterprise has a total market capitalisation of ₹1.08 trillion. Apollo Hospitals to list digital health, pharmacy unit Apollo Hospitals plans to demerge its omnichannel pharmacy distribution, Apollo 24|7 digital platform, and remote telehealth division into a new entity, according to an exchange filing on Monday. Simultaneously, Keimed Pvt Ltd will be merged into the same entity. This move will allow Apollo Hospitals shareholders to directly own shares in the newly created, integrated healthcare entity, the company said in the statement. The combined company is projected to have revenues of approximately ₹16,300 crore in the financial year 2024–25. It aims to reach a revenue run-rate of ₹25,000 crore by the end of the financial year 2026-27, with a gross merchandise value (GMV) of ₹28,000 crore and targeted Ebitda margins of around 7 per cent, according to the investor presentation report. The listing of the entity is expected to take place within 18 to 21 months. Under the scheme, shareholders of AHEL will receive 195.2 shares of the new company for every 100 shares held in AHEL. In addition, subject to regulatory approvals, AHEL also plans to increase the new entity's stake in Apollo Pharmacies Ltd by acquiring the remaining 74.5 per cent stake in Apollo Medicals Pvt. Ltd (AMPL), of which APL is currently a wholly owned subsidiary. JM Financial on Apollo Hospitals With approximately 6,600 outlets, 1.4 times that of the second-largest player, the company operates the largest pharmacy network in India. The integration of the Apollo 24|7 online platform and the merger with Keimed are expected to accelerate growth, enabling expansion in online sales and strengthening of private label offerings, the brokerage said. With a better product mix, realisation of synergies, and increased operating leverage, segmental Ebitda margins are projected to improve from 1.8 per cent to 6.5 per cent by financial year 2027–28, supported by a top-line compound annual growth rate (CAGR) of 20.2 per cent between financial years 2024–25 and 2027–28, it said. Apollo Hospitals Q4 results The company reported a consolidated net profit of ₹389.6 crore for the quarter ended March 31, 2025 (Q4 FY25), marking a growth of nearly 54 per cent from ₹253.8 crore in the year-ago period (Q4 FY24). Revenue from operations in Q4 FY25 stood at ₹5,592.2 crore, up around 13.11 per cent from ₹4,943.9 crore in Q4 FY24. On a quarter-on-quarter basis, revenue rose moderately from ₹5,526.9 crore in Q3 FY25.
Mint
16 hours ago
- Mint
Apollo Hospitals share price jumps over 4% 50 52-week high on plans to list digital health, pharmacy businesses
Apollo Hospitals share price rallied over 4% to hit 52-week high on Tuesday after the company's board approved separate listing of its omnichannel pharmacy and digital health businesses within 18-21 months, as part of reorganisation exercise to unlock value. Apollo Hospitals shares jumped as much as 4.7% to a fresh high of ₹ 7,583.30 apiece on the BSE. The board of directors of Apollo Hospitals Enterprise and Apollo HealthCo, a subsidiary of the healthcare major, have accorded in-principle approval for the composite scheme of arrangement. The scheme entails the demerger of the Omni Channel Pharma and Digital Health business - comprising the telehealth business of Apollo and its investment in Apollo HealthCo Ltd - into a new entity. Following the demerger, the scheme provides for the amalgamation of Apollo HealthCo with the new entity. This will subsequently be followed by the amalgamation of Keimed Pvt Ltd with NewCo (new entity). 'The proposed transaction will result in the creation of the largest, integrated omni-channel healthcare eco-system with a FY25 revenue of ₹ 16,300 crores ($1.9 billion) in FY25,' Apollo Hospitals said in a release. The business will comprise - Apollo 24/7, the digital health platform; the offline pharma distribution of AHL; Third party pharma distribution of Keimed; and telehealth services of AHEL. 'The combination of businesses is anticipated to generate substantial synergies, and the New Co is expected to achieve a revenue run rate of ₹ 25,000 crores ($2.9 billion) by FY27,' the company added. Upon the effectiveness of the Scheme, the new entity will become an Indian Owned and Controlled Company (IOCC) and will apply for listing on the stock exchanges, it added. The listing is expected within 18-21 months, the healthcare major said. For every 100 shares of Apollo Hospitals Enterprise, the shareholders of Apollo Hospitals Enterprise will receive 195.2 shares of NewCo, enabling their direct participation in the value unlock. Upon becoming an IOCC, the entity also proposes to consolidate the front-end pharmacy business by acquiring the remaining 74.5% stake in Apollo Medicals Pvt Ltd (AMPL), which owns 100% of Apollo Pharmacies Limited (APL), it said. Apollo Hospitals Enterprise will retain a 15% stake in the 'NewCo' to ensure an integrated, seamless, and comprehensive healthcare offering across the patient lifecycle, it added. Apollo Hospitals Enterprise MD Suneeta Reddy said the proposal enables the healthcare provider's shareholders to gain direct shareholding to country's largest omni-channel pharmacy and digital health platform. Apollo Hospitals share price has risen 9% in one month, and more than 12% in three months. The stock is up just 1% on a year-to-date (YTD) basis, but has rallied 22% in one year. Apollo Hospitals shares have delivered mutlibagger returns of 466% in the past five years. At 10:15 AM, Apollo Hospitals share price was trading 3.28% higher at ₹ 7,480.00 apiece on the BSE. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
